11 citations
,
April 1982 in “Journal of the Forensic Science Society”
This study found that specific enzymes could be detected in fresh hairsheathcells, with most remaining detectable in older cells, except for Adenylate kinase and Esterase D.
9 citations
,
June 2020 in “Tissue Engineering and Regenerative Medicine”
This study found that applying HHORSC exosomes may enhance the hair inductivity of dermal papilla cells, potentially improving treatments for hair loss.
This study describes a new tissue culture method that successfully induces outer root sheathcells from hair follicles to differentiate into a multilayered epithelium with characteristics similar to normal interfollicular epidermis.
18 citations
,
December 2020 in “Frontiers in cell and developmental biology”
This study found that extracellular vesicles from low-passage dermal papilla cells may activate hair growth by delivering miR-140-5p, which downregulates BMP2 signaling, suggesting potential therapeutic targets for alopecia.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
Hair growth relies on mechanical forces, not just chemicals, with tissue acting like a motor. Minoxidil and finasteride help, but maintaining tissue elasticity and addressing mechanical issues are essential.
Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.